Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.

Zhang D, Thimmapaya R, Zhang XF, Anderson DJ, Baranowski JL, Scanio M, Perez-Medrano A, Peddi S, Wang Z, Patel JR, DeGoey DA, Gopalakrishnan M, Honore P, Yao BB, Surowy CS.

J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.

PMID:
21723881
2.

The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.

Padilla K, Wickenden AD, Gerlach AC, McCormack K.

Neurosci Lett. 2009 Nov 13;465(2):138-42. doi: 10.1016/j.neulet.2009.08.071. Epub 2009 Sep 3.

PMID:
19733209
3.

Structural determinants of M-type KCNQ (Kv7) K+ channel assembly.

Schwake M, Athanasiadu D, Beimgraben C, Blanz J, Beck C, Jentsch TJ, Saftig P, Friedrich T.

J Neurosci. 2006 Apr 5;26(14):3757-66.

4.

The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.

Gunthorpe MJ, Large CH, Sankar R.

Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Review.

5.
6.

Recent developments on KCNQ potassium channel openers.

Wua YJ, Dworetzky SI.

Curr Med Chem. 2005;12(4):453-60. Review.

PMID:
15720253
7.

Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.

Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA.

Mol Pharmacol. 2000 Aug;58(2):253-62.

8.

Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B.

Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14.

9.

K(V)7/KCNQ channels are functionally expressed in oligodendrocyte progenitor cells.

Wang W, Gao XF, Xiao L, Xiang ZH, He C.

PLoS One. 2011;6(7):e21792. doi: 10.1371/journal.pone.0021792. Epub 2011 Jul 5.

10.

Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.

Xiong Q, Sun H, Zhang Y, Nan F, Li M.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3128-33. doi: 10.1073/pnas.0712256105. Epub 2008 Feb 12.

11.

Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.

Zhou P, Yu H, Gu M, Nan FJ, Gao Z, Li M.

Proc Natl Acad Sci U S A. 2013 May 21;110(21):8726-31. doi: 10.1073/pnas.1302167110. Epub 2013 May 6.

12.

Activation of KCNQ2/3 potassium channels by novel pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives.

Jia C, Qi J, Zhang F, Mi Y, Zhang X, Chen X, Liu L, Du X, Zhang H.

Pharmacology. 2011;87(5-6):297-310. doi: 10.1159/000327384. Epub 2011 May 17.

PMID:
21577044
13.

Drosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.

Cavaliere S, Hodge JJ.

PLoS One. 2011;6(9):e23898. doi: 10.1371/journal.pone.0023898. Epub 2011 Sep 7.

14.

Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.

Tatulian L, Brown DA.

J Physiol. 2003 May 15;549(Pt 1):57-63. Epub 2003 Apr 17.

15.

Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.

Kalappa BI, Soh H, Duignan KM, Furuya T, Edwards S, Tzingounis AV, Tzounopoulos T.

J Neurosci. 2015 Jun 10;35(23):8829-42. doi: 10.1523/JNEUROSCI.5176-14.2015.

16.

Sequence determinants of subtype-specific actions of KCNQ channel openers.

Wang AW, Yang R, Kurata HT.

J Physiol. 2017 Feb 1;595(3):663-676. doi: 10.1113/JP272762. Epub 2016 Sep 23.

PMID:
27506413
17.

Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model.

Zheng Q, Fang D, Liu M, Cai J, Wan Y, Han JS, Xing GG.

Pain. 2013 Mar;154(3):434-48. doi: 10.1016/j.pain.2012.12.005. Epub 2012 Dec 20.

PMID:
23352759
18.

Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.

Miceli F, Soldovieri MV, Martire M, Taglialatela M.

Curr Opin Pharmacol. 2008 Feb;8(1):65-74. Epub 2007 Dec 3. Review.

PMID:
18061539
19.

Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.

Ihara Y, Tomonoh Y, Deshimaru M, Zhang B, Uchida T, Ishii A, Hirose S.

PLoS One. 2016 Feb 24;11(2):e0150095. doi: 10.1371/journal.pone.0150095. eCollection 2016.

20.

Development and validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel openers using QPatch HT.

Zhang XF, Zhang D, Surowy CS, Yao B, Jarvis MF, McGaraughty S, Neelands TR.

Assay Drug Dev Technol. 2013 Feb;11(1):17-24. doi: 10.1089/adt.2012.446. Epub 2012 Sep 24.

PMID:
23002961

Supplemental Content

Support Center